Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia

Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with progressive bone pain, muscle weakness, and fragility fractures. TIO is characterized by hypophosphatemia, excess renal phosphate ex...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of internal medicine 2023-03, Vol.293 (3), p.309-328
Hauptverfasser:	Jan de Beur, Suzanne M., Minisola, Salvatore, Xia, Wei‐bo, Abrahamsen, Bo, Body, Jean‐Jacques, Brandi, Maria Luisa, Clifton‐Bligh, Roderick, Collins, Michael, Florenzano, Pablo, Houillier, Pascal, Imanishi, Yasuo, Imel, Erik A., Khan, Aliya A., Zillikens, M. Carola, Fukumoto, Seiji
Format:	Artikel
Sprache:	eng
Schlagworte:	25-Hydroxyvitamin D Alkaline phosphatase Autoimmune diseases Chronic pain consensus Creatinine Diagnosis diagnostic tests/routine Fibroblast growth factor 23 Fibroblast Growth Factors Fractures Fractures, Bone Fragility Growth factors Health services Humans Hypophosphatemia Hypophosphatemia - complications Life Sciences Mesenchyme Muscles Myopathy Osteomalacia Pain Paraneoplastic syndrome Paraneoplastic Syndromes - diagnosis Paraneoplastic Syndromes - etiology Paraneoplastic Syndromes - therapy Parathyroid hormone Patients Phosphate Phosphates - therapeutic use Reabsorption Recognition referral and consultation Renal function Review Reviews Tumors tumor‐induced osteomalacia Vitamin D
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!